A novel homozygous UMOD mutation reveals gene dosage effects on uromodulin processing and urinary excretion
Author(s) -
Noel Edwards,
Eric Olinger,
Jennifer Adam,
Michael Kelly,
Guglielmo Schiano,
Simon A. Ramsbottom,
Richard Sandford,
Olivier Devuyst,
John A. Sayer
Publication year - 2017
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfx066
Subject(s) - tamm–horsfall protein , urinary system , proband , heterozygote advantage , compound heterozygosity , medicine , mutation , genetics , gene , genotype , endocrinology , biology
Heterozygous mutations in UMOD encoding the urinary protein uromodulin are the most common genetic cause of autosomal dominant tubulointerstitial kidney disease (ADTKD). We describe the exceptional case of a patient from a consanguineous family carrying a novel homozygous UMOD mutation (p.C120Y) affecting a conserved cysteine residue within the EGF-like domain III of uromodulin. Comparison of heterozygote and homozygote mutation carriers revealed a gene dosage effect with unprecedented low levels of uromodulin and aberrant uromodulin fragments in the urine of the homozygote proband. Despite an amplified biological effect of the homozygote mutation, the proband did not show a strikingly more severe clinical evolution nor was the near absence of urinary uromodulin associated with urinary tract infections or kidney stones.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom